FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018411749> ?p ?o ?g. }

• W2018411749 endingPage "600" @default.
• W2018411749 startingPage "600" @default.
• W2018411749 abstract "Cerebral palsy (CP) includes a group of nonprogressive disorders of movement and posture thought to result from adverse events during fetal or infant brain development, such as preterm birth, placental abruption, infection, or physical abuse. However, there has been increasing interest in the genetic aspects of CP, focusing not only on genes that are associated with hereditary spastic syndromes but also on those that might affect the intrauterine milieu, predispose to stroke, or alter the brain’s response to injury.1 One of the prominent candidates undergoing increasing study is Apolipoprotein E (ApoE), a gene with three alleles (ε2, ε3, ε4) that codes for lipid transport proteins that participate in neuronal maintenance and repair. Interest in the relationship between ApoE and CP was sparked by Kuroda et al.’s finding that the frequency of ApoEε4 was higher in children with CP (12/100) than in an age-sex-race-matched comparison group of unaffected children (4/100).2 They concluded that ApoEε4 is a risk factor for CP. One significant problem with this study, conducted in Chicago, USA, is that the frequency of ApoEε4 in the comparison group was far lower than that of other reports of ApoE in healthy children (12/100 to 32/100). Since ApoE allele frequencies are more dependent on specific geographic origins than on self-identified racial group membership, matching based on race or ethnicity alone could result in misleading data, especially in a cosmopolitan city like Chicago whose citizens typically have very diverse family roots, regardless of what racial group they claim to belong to. It is possible, perhaps likely, that the comparison group, despite racial matching, had ancestors from world regions with low ApoEε4 frequencies rather than a lower risk of CP. In their study, Braga et al.3 report an increased prevalence of the ε2 but not ε4 among individuals with CP in Brazil. Similarly, McMichael et al.4 found no association between ApoEε4 and cerebral risk in a large population-based sample in southern Australia. Each of these studies lessened the risk of spurious results due to ethnic diversity by utilizing more homogenous samples, especially in Australia, and refuted the implication that ApoEε4 is a risk factor for CP. It seems more likely that ApoE is involved in modifying the brain’s response to injury, rather than affecting risk of injury itself. In contrast to adults, among whom ApoE is a risk factor for Alzheimer disease and worse outcome after traumatic brain injury and other neurological disorders, there is growing evidence that ApoEε4 may be protective in the developing brain.5ApoEε4 has been shown to favor embryonic development and fetal survival,6 preserve brain development after chronic diarrhea and malnutrition,7 and lessen the severity of perinatal brain injury.8 Conversely, the ε2 allele, protective against Alzheimer disease, appears detrimental to fetal well-being9 and to developmental outcomes for infants undergoing surgery for congenital heart disease.10 Is ApoE simply the CP gene of interest du jour? Does it hold promise beyond a theoretical understanding of factors that explain differences in outcome as a possible therapy? While much of the attention regarding the therapeutic potential of a modified ApoE molecule is focused on Alzheimer and cardiovascular disease, the possibility exists for its use in prevention or amelioration of CP. The relationship between the various polymorphisms of ApoE and CP should be explored further, with the expectation that the role of its various alleles in children, particularly during rapid brain development, may be opposite from that in adults. If an ApoE treatment proves successful in adults, it could be tragic to assume the same form of treatment would be beneficial for newborn infants." @default.
• W2018411749 created "2016-06-24" @default.
• W2018411749 creator A5019372730 @default.
• W2018411749 date "2010-01-05" @default.
• W2018411749 modified "2023-10-17" @default.
• W2018411749 title "Apolipoprotein E genotype and cerebral palsy" @default.
• W2018411749 cites W2072430086 @default.
• W2018411749 cites W2079817702 @default.
• W2018411749 cites W2091245222 @default.
• W2018411749 cites W2094637617 @default.
• W2018411749 cites W2108027291 @default.
• W2018411749 cites W2114068891 @default.
• W2018411749 cites W2166512828 @default.
• W2018411749 cites W4253151840 @default.
• W2018411749 cites W1868647857 @default.
• W2018411749 doi "https://doi.org/10.1111/j.1469-8749.2009.03476.x" @default.
• W2018411749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20059521" @default.
• W2018411749 hasPublicationYear "2010" @default.
• W2018411749 type Work @default.
• W2018411749 sameAs 2018411749 @default.
• W2018411749 citedByCount "5" @default.
• W2018411749 countsByYear W20184117492013 @default.
• W2018411749 countsByYear W20184117492015 @default.
• W2018411749 countsByYear W20184117492020 @default.
• W2018411749 countsByYear W20184117492023 @default.
• W2018411749 crossrefType "journal-article" @default.
• W2018411749 hasAuthorship W2018411749A5019372730 @default.
• W2018411749 hasBestOaLocation W20184117491 @default.
• W2018411749 hasConcept C104317684 @default.
• W2018411749 hasConcept C118552586 @default.
• W2018411749 hasConcept C126322002 @default.
• W2018411749 hasConcept C135763542 @default.
• W2018411749 hasConcept C15744967 @default.
• W2018411749 hasConcept C180754005 @default.
• W2018411749 hasConcept C2776035688 @default.
• W2018411749 hasConcept C2778163477 @default.
• W2018411749 hasConcept C2779134260 @default.
• W2018411749 hasConcept C2779421357 @default.
• W2018411749 hasConcept C46312422 @default.
• W2018411749 hasConcept C54355233 @default.
• W2018411749 hasConcept C57089818 @default.
• W2018411749 hasConcept C62746215 @default.
• W2018411749 hasConcept C71924100 @default.
• W2018411749 hasConcept C86803240 @default.
• W2018411749 hasConceptScore W2018411749C104317684 @default.
• W2018411749 hasConceptScore W2018411749C118552586 @default.
• W2018411749 hasConceptScore W2018411749C126322002 @default.
• W2018411749 hasConceptScore W2018411749C135763542 @default.
• W2018411749 hasConceptScore W2018411749C15744967 @default.
• W2018411749 hasConceptScore W2018411749C180754005 @default.
• W2018411749 hasConceptScore W2018411749C2776035688 @default.
• W2018411749 hasConceptScore W2018411749C2778163477 @default.
• W2018411749 hasConceptScore W2018411749C2779134260 @default.
• W2018411749 hasConceptScore W2018411749C2779421357 @default.
• W2018411749 hasConceptScore W2018411749C46312422 @default.
• W2018411749 hasConceptScore W2018411749C54355233 @default.
• W2018411749 hasConceptScore W2018411749C57089818 @default.
• W2018411749 hasConceptScore W2018411749C62746215 @default.
• W2018411749 hasConceptScore W2018411749C71924100 @default.
• W2018411749 hasConceptScore W2018411749C86803240 @default.
• W2018411749 hasIssue "7" @default.
• W2018411749 hasLocation W20184117491 @default.
• W2018411749 hasLocation W20184117492 @default.
• W2018411749 hasOpenAccess W2018411749 @default.
• W2018411749 hasPrimaryLocation W20184117491 @default.
• W2018411749 hasRelatedWork W1982661683 @default.
• W2018411749 hasRelatedWork W2068963435 @default.
• W2018411749 hasRelatedWork W2094823974 @default.
• W2018411749 hasRelatedWork W2136769627 @default.
• W2018411749 hasRelatedWork W2355380693 @default.
• W2018411749 hasRelatedWork W2375419527 @default.
• W2018411749 hasRelatedWork W2385193103 @default.
• W2018411749 hasRelatedWork W2398434463 @default.
• W2018411749 hasRelatedWork W2409087048 @default.
• W2018411749 hasRelatedWork W2779806072 @default.
• W2018411749 hasVolume "52" @default.
• W2018411749 isParatext "false" @default.
• W2018411749 isRetracted "false" @default.
• W2018411749 magId "2018411749" @default.
• W2018411749 workType "article" @default.